Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells.

AKT isoforms are expressed in prostate cancer and their expression and localization have different associations with clinical characteristics. However, the distinct roles of the AKT isoforms in prostate cancer cells are largely unknown. In the present study, we demonstrate distinct roles for AKT1 and AKT2 in cell growth and migration. Ablation of AKT1 and AKT2 decreased the proliferation of the androgen-independent cell line PC-3, although by different mechanisms. AKT1 ablation induced loss of cell adhesion and subsequent apoptosis. AKT2 (but not AKT1) ablation promoted cell cycle arrest at G0/G1, associated with downregulation of cyclin D, CDK6 and CDK2, and upregulation and cytoplasmic-to-nuclear redistribution of p27. The increase of p27 protein levels was due to more gene transcription and an increase in protein stability. The increased stability of p27 was induced by delocalisation of Skp2 and a lower level of p27 phosphorylation at Thr187. AKT1 and AKT2 ablation inhibited and stimulated PC-3 cell migration, respectively. An AKT isoform-specific function could be associated with its subcellular localization. We found that AKT1 and AKT2 were mainly localised in the cytoplasm and nucleus, respectively. In androgen-sensitive cell line LNCaP, the ablation of AKT1 or AKT2 caused apoptosis but in androgen-independent LNCaP sublines, the effect of AKT1 ablation was lower; whereas no changes were observed after AKT2 ablation. Taken together, our data show that AKT1 and AKT2 have non-redundant roles in the regulation of PC-3 cell proliferation and migration. These could be explained by their subcellular localization and/or the specific regulation of downstream effectors. Furthermore, contribution of AKT isoforms to the progression of prostate cancer may change from an androgen-sensitive to a hormone-refractory stage. These findings may help design new targeted strategies for inhibiting AKT isoforms in prostate cancer.

[1]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[2]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[3]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[4]  J. Frahm,et al.  Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis , 2005, Development.

[5]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[6]  S. Chien,et al.  mTOR is the rapamycin‐sensitive kinase that confers mechanically‐induced phosphorylation of the hydrophobic motif site Thr(389) in p70S6k , 2007, FEBS letters.

[7]  B. Karlan,et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.

[8]  Takashi Tsuruo,et al.  Akt-dependent Phosphorylation of p27Kip1Promotes Binding to 14-3-3 and Cytoplasmic Localization* , 2002, The Journal of Biological Chemistry.

[9]  A. Toker,et al.  Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction , 2009, Nature Cell Biology.

[10]  J. Angulo,et al.  EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. , 2012, Carcinogenesis.

[11]  W. Yung,et al.  Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. , 1999, Cancer research.

[12]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[13]  Chia-Hsin Chan,et al.  Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression , 2010, TheScientificWorldJournal.

[14]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[15]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[16]  J. Albrecht,et al.  S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy. , 2011, The Journal of clinical investigation.

[17]  I. Roninson,et al.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. , 2001, Genes & development.

[18]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[19]  Z. Lu,et al.  AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  A. Friedl,et al.  Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. , 2000, Cancer research.

[21]  N. Hay,et al.  The effect Akt2 deletion on tumor development in Pten+/− mice , 2011, Oncogene.

[22]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[23]  Ludger Hengst,et al.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy , 2008, Nature Reviews Cancer.

[24]  S. Ropero,et al.  EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. , 2007, Neoplasia.

[25]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[26]  M. Birnbaum,et al.  Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration* , 2006, Journal of Biological Chemistry.

[27]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[28]  K. Nielsen,et al.  Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.

[29]  H. Koo,et al.  Roles of AKT1 and AKT2 in non‐small cell lung cancer cell survival, growth, and migration , 2011, Cancer science.

[30]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[31]  T. Sakai,et al.  Sp1 and NF-Y Synergistically Mediate the Effect of Vitamin D3 in the p27Kip1 Gene Promoter That Lacks Vitamin D Response Elements* , 1999, The Journal of Biological Chemistry.

[32]  James M. Roberts,et al.  p27Kip1 modulates cell migration through the regulation of RhoA activation. , 2004, Genes & development.

[33]  M. Birnbaum,et al.  Differential regulation of Akt/protein kinase B isoforms during cell cycle progression , 2009, FEBS letters.

[34]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[35]  S. Meloche,et al.  Phosphorylation of Ser72 does not regulate the ubiquitin ligase activity and subcellular localization of Skp2 , 2010, Cell cycle.

[36]  K. Nakashiro,et al.  Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. , 2010, Biochemical and biophysical research communications.

[37]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[38]  Hoyun Lee,et al.  Ablation of Akt2 Induces Autophagy through Cell Cycle Arrest, the Downregulation of p70S6K, and the Deregulation of Mitochondria in MDA-MB231 Cells , 2011, PloS one.

[39]  S. Batra,et al.  Establishment and characterization of androgen‐independent human prostate cancer LNCaP cell model , 2002, The Prostate.

[40]  James M. Roberts,et al.  Cyclin E-CDK2 is a regulator of p27Kip1. , 1997, Genes & development.

[41]  G. Bartsch,et al.  Androgen axis in prostate cancer , 2006, Journal of cellular biochemistry.

[42]  T. McGraw,et al.  The Akt kinases: Isoform specificity in metabolism and cancer , 2009, Cell cycle.

[43]  P. Pandolfi,et al.  Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB , 2009, Nature Cell Biology.

[44]  R. Medema,et al.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.

[45]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[46]  M. Pagano,et al.  Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization , 2010, Cell cycle.

[47]  R. Adam,et al.  The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. , 1999, Cancer research.

[48]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[49]  S. Naber,et al.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. , 2007, Cancer research.

[50]  J. Bartlett,et al.  Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients , 2008, British Journal of Cancer.

[51]  G. Mills,et al.  Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. , 2009, Cancer research.

[52]  Ping-Hui Tseng,et al.  Bcl-xL Mediates a Survival Mechanism Independent of the Phosphoinositide 3-Kinase/Akt Pathway in Prostate Cancer Cells* , 2003, Journal of Biological Chemistry.

[53]  M. Birnbaum,et al.  Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis , 2005 .

[54]  Hong Sun,et al.  p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27 , 1999, Current Biology.

[55]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.